In addition, high levels of ANXA1 expression are consistently observed in triple-negative breast cancer (TNBC), compared with other breast cancer subtypes [13–15], suggesting that it might be a promising therapeutic target in these tumours. The gene discussed is ANXA1; the disease is triple-negative breast carcinoma.